Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

Fig. 3

Response to FGF401. Waterfall plot for best percentage change from baseline in sum of the longest diameters based on local radiology review per RECIST v1.1 in A single agent phase I patients with HCC, B single agent Phase I patients with other solid tumors, C single agent Phase II group 1 patients with HCC [Asian countries], D single agent Phase II group 2 patients with HCC [non-Asian countries], E single agent Phase II group 3 patients with other solid tumors, F combination phase I patients with HCC. PD, progressive disease; PR, partial response; SD, stable disease; UNK, unknown

Back to article page